Based on the latest rules of the Hong Kong Stock Exchange (HKEX) as of August 2025, this comprehensive listing guide combines practical operational points to help enterprises efficiently prepare for and achieve compliant listing:
**I. Core Financial and Market Capitalization Requirements**
**1. Main Board Regular Enterprise Tests**
Profit Test: Net profit ≥HK$35 million in the most recent year, cumulative ≥HK$45 million in the previous two years (total of HK$80 million over three years).
Market Cap Test: Market capitalization ≥HK$500 million at listing (if adopting market cap/revenue test, revenue ≥HK$500 million and market cap ≥HK$4 billion required).
Cash Flow Test: Cash flow ≥HK$100 million over the past three years, with market cap ≥HK$2 billion.
**2. Special Industry Channels (Biotech Companies, Chapter 18A)**
No revenue requirement, but must satisfy: - At least one core product has passed the concept stage (such as completion of Phase I clinical trials); - Listing market cap ≥HK$1.5 billion; - Management team with stable operations ≥2 years; - Working capital covering 125% of expenses for 12 months post-listing.
**II. Equity Structure and Liquidity Requirements (Effective August 4, 2025)**
**1. Tiered Standards for Public Float**
**2. Free Float Requirements** Non-A+H companies: Free float ≥10% with market cap ≥HK$50 million (or ≥HK$600 million); A+H companies: Free float ≥5% with market cap ≥HK$600 million.
**3. Continuing Shareholding Requirements (Under Consultation)** Alternative threshold: 10% shareholding + HK$1 billion market cap; insufficient cases will be flagged with stock codes and given an 18-month remediation period.
**III. Corporate Governance Framework Upgrades (Effective July 1, 2025)**
**1. Board Effectiveness Enhancement** Mandatory annual director training (ESG, legal updates, risk internal controls); New directors must complete 12-24 hours of training. Biennial board performance evaluation with disclosure of skills matrix and improvement plans.
**2. Independent Director Independence Safeguards** Term limit ≤9 years, with 3-year "cooling-off period" required after exceeding limit; Independent directors limited to ≤6 Hong Kong-listed companies (existing enterprises must comply by 2028).
**3. Diversity Policy** Nomination committee must include at least one member of different gender; Mandatory disclosure of gender ratios for senior management and non-senior management.
**IV. New IPO Pricing and Allocation Mechanisms (Effective August 4, 2025)**
Issuers must choose one of the following two mechanisms:
Practical Note: Minimum allocation ratio for bookbuilding portion reduced from 50% to 40% to attract more institutional investors. Cornerstone investor lock-up period remains 6 months (phased unlocking proposal not adopted).
**V. Special Industry Listing Channels**
**1. Biotech and Specialist Technology Companies (Chapters 18A/18C)** "Tech Fast Track" service: The Exchange has established professional teams to provide pre-listing guidance, addressing core product requirements, sophisticated investor qualifications, and other issues. Confidential submission of applications: Allows confidential filing to avoid premature disclosure of proprietary technology or strategies.
**2. Simplified WVR Structure Recognition** Companies fully complying with Chapters 18A/18C automatically satisfy innovative industry company requirements (no need for duplicate certification).
**VI. Continuous Compliance Management**
**1. Enhanced Information Disclosure** H-share companies must disclose monthly shareholding change reports within 5 trading days of month-end; ESG reports must be published independently, with explanations required for non-dividend payments.
**2. Integrated Risk Internal Control System** Incorporation of COSO risk management framework with annual board effectiveness assessment; Single guarantees exceeding 10% of net assets or cumulative guarantees exceeding 30% of total assets require shareholder approval.
**3. Shareholder Return Policy** Mandatory disclosure of dividend basis (e.g., mature enterprises with cash dividends ≥80%).
**VII. Transition Arrangements and Operational Recommendations**
**1. Existing Enterprise Compliance Pathway** Excessive independent director concurrent positions: Must be rectified by 2028. Board diversity: Immediate implementation of gender composition requirements.
**2. New Applicant Considerations** Companies publishing listing documents after August 4, 2025 must directly comply with new regulations; VIE structure listing applications should allow additional time for mainland filing (approximately 4-5 months).
**3. Common Deficiency Cases** Undisclosed share pledges: Former Xinyuan Property Services director publicly censured for failing to disclose subsidiary deposit pledges. Circumventing related party transaction approvals: Fantasia Holdings directors underwent mandatory training for asset sales without shareholder approval.
**Enterprise Action Roadmap**
**Regulatory Trend Insights**: The Exchange's regulatory logic has shifted from "formal compliance" to "governance capability building." Enterprises need to transform compliance costs into competitive advantages (such as matching board skills matrix with strategic blueprints).
Data Sources: HKEX consultation papers and other sources (latest policies as of August 2025).
For specific operational case details, relevant webpage content can be further extracted.